BioSpaceOriginal article
Merck axes Alzheimer’s study, adding to partner Neuphoria’s mounting woes
Phase 2negativeNegative
AI Analysis
Summary
Merck has discontinued a mid-stage Alzheimer's disease study, delivering another setback to partner Neuphoria Therapeutics, which is already undergoing strategic review following a Phase 3 failure in social anxiety disorder last year.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Mid-stage Alzheimer's study discontinued
Importance:6/10
Sentiment:
-0.80
Alzheimer's diseasePhase 2 failurestudy discontinuationpartnership impactsocial anxiety disorder
Related Companies
Read the original article
Published by BioSpace on July 2, 2026 11:52 AM